Benitec Biopharma Ltd (BNTC)
TipRanksstock market overviewBenitec Biopharma Stock Analysis & Ratings

Benitec Biopharma Stock Analysis & Ratings


BNTC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.67 - $4.78
Previous Close$0.85
Average Volume (3M)2.30M
Market CapN/A
Enterprise ValueN/A
P/E Ratio-0.4
Next EarningsSep 28, 2022
Dividend YieldN/A
Smart ScoreN/A
EPS (TTM)-2.10
Shares Outstanding8,171,690
Standard Deviation0.22
10 Day Avg. Volume69,709
30 Day Avg. Volume2,299,193
P/B Ratio0.94
P/S Ratio98.99
P/CF Ratio2.80
P/FCF Ratio-0.60
Total Debt$194.00K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside1073.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Benitec Biopharma’s price range in the past 12 months?
Benitec Biopharma lowest stock price was $0.67 and its highest was $4.78 in the past 12 months.
    What is Benitec Biopharma’s market cap?
    Currently, no data Available
    What is Benitec Biopharma’s price target?
    The average price target for Benitec Biopharma is $10.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $10.00 ,the lowest forecast is $10.00. The average price target represents 1073.02% Increase from the current price of $0.853.
      What do analysts say about Benitec Biopharma?
      Benitec Biopharma’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
        When is Benitec Biopharma’s upcoming earnings report date?
        Benitec Biopharma’s upcoming earnings report date is Sep 28, 2022 which is in 45 days.
          How were Benitec Biopharma’s earnings last quarter?
          Benitec Biopharma released its earnings results on May 16, 2022. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.44 by $0.04.
            Is Benitec Biopharma overvalued?
            According to Wall Street analysts Benitec Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Benitec Biopharma pay dividends?
              Benitec Biopharma pays a Notavailable dividend of $0.03 which represents an annual dividend yield of N/A. Benitec Biopharma’s last Notavailable dividend payment was on Jun 08, 2018. Benitec Biopharma’s upcoming ex-dividend date is Jun 01, 2018
                What is Benitec Biopharma’s EPS estimate?
                Benitec Biopharma’s EPS estimate is -$0.28.
                  How many shares outstanding does Benitec Biopharma have?
                  Benitec Biopharma has 8,171,690 shares outstanding.
                    What happened to Benitec Biopharma’s price movement after its last earnings report?
                    Benitec Biopharma reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.44. Following the earnings report the stock price went down -8.475%.
                      Which hedge fund is a major shareholder of Benitec Biopharma?
                      Currently, no hedge funds are holding shares in BNTC


                      Benitec Biopharma Stock Analysis

                      Smart ScoreNot Ranked
                      This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Benitec Biopharma Ltd

                      Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in North Sydney, Australia.

                      Similar Stocks
                      Price & Change
                      Gilead Sciences
                      Vertex Pharmaceuticals

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis